Portal de investigación
REGISTRO DE PACIENTES CON COLITIS COLAGENA TRATADOS CON AZATIOPRINA Y/O MERCAPTOPURINA.
Datos básicos
- Código:
- HMT-AZA-2014-01
- Protocolo:
- HMT-AZA-2014-01
- EUDRACT:
- NCT:
- Centro:
- Dotación:
- Año de incio:
- Año de finalización:
- 2015
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
1-Butanol absorption in poly(styrene-divinylbenzene) ion exchange resins for catalysis
Pérez-Maciá MA; (...); Aleman C
Article. 10.1039/c5sm02168e. 2015
A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence.
Cerrillo E; (...); Beltrán B
Article. 10.1093/ibd/izz053. 2019
Acute myocardial infarction in a patient with a recent diagnosis of Crohn's disease
Navarro, B; (...); Iborra, M
Editorial Material. 10.1016/j.gastrohep.2018.05.008. 2019
Adherence to endoscopic surveillance guidelines for advanced lesions and colorectal cancer in Inflammatory Bowel Disease in Spain: a collaborative study of AEG and GETECCU
Ballester Ferre, M. P.; (...); Minguez, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.727. 2021
Adsorptive granulocyte/monocyte apheresis use in severe ulcerative colitis and determination of changes in plasma cytokines
Beltran, B; (...); Nos, P
Article. 10.1002/jca.21552. 2018
Alpha-defensins (alpha-Defs) in Crohn's disease: decrease of ileal alpha-Def 5 via permanent methylation and increase in plasma alpha-Def 1-3 concentrations offering biomarker utility
Cerrillo, E; (...); Beltran, B
Article. 10.1111/cei.13085. 2018
Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis
Taxonera, Carlos; (...); Alba, Cristina
Article. 10.1111/apt.16964. 2022
Association of golimumab trough concentrations during maintenance with endoscopic and histologic remission in patients with ulcerative colitis
Taxonera Samso, C.; (...); Alba, C.
Meeting Abstract. 2022
Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease
SÁEZ, E.; (...); BELTRÁN, B.
Article. 10.3390/nu11051062. 2019
Biomarkers response to anti-TNF treatment in Crohn's disease through the intestinal microbiota
Sanchis, L; (...); Cortes, X
Meeting Abstract. 2020
Catalase inhibition can modulate the ability of peripheral blood T cells to undergo apoptosis in Crohn's disease.
Moret-Tatay, Ines; (...); Beltran, Belen
Article. 10.1093/cei/uxad134. 2024
Certification of integral care IBD Units: Evaluation of a certification program (CUE)
Barreiro-de Acosta, M; (...); GETECCU
Meeting Abstract. 2020
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Calafat, Margalida; (...); Domenech, Eugeni
Article. 10.1177/17562848231221713. 2024
Clinical characteristics and management of Crohn's disease in patients with residual disease after surgery compared with curative surgery: Results from PRACTICROHN study
Domenech, E; (...); Julia, B
Meeting Abstract. 2018
Clinical characteristics, associated malignancies and management of primary sclerosing colangitis in inflammatory bowel disease patients: A Spanish nationwide study based on the ENEIDA registry
Guerra, I; (...); Gisbert, JP
Meeting Abstract. 2018
Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicenter retrospective cohort study.
Guerra I; (...); Gisbert JP
Article. 10.1093/ecco-jcc/jjz094. 2019
Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-alpha drug failure
Saez-Gonzalez, E; (...); Beltran, B
Letter. 10.1016/j.dld.2018.01.124. 2018
Correlation between adalimumab serum levels and remission after the induction phase in Crohn's Disease patients
Chaparro, M.; (...); Gisbert, J. P.
Article. 2015
Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease
Pous-Serrano, Salvador; (...); Nos, Pilar
Article. 10.1016/j.jss.2017.02.064. 2017
Corrigendum to “Recomendaciones del Grupo Español de Trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento” [Gastroenterología y Hepatología 2020;43(10):649-658].
Barreiro-de Acosta M; (...); Nos P
Correction. 10.1016/j.gastrohep.2021.02.001. 2021
Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group
Fernández-Bañares F; (...); Gisbert JP
Article. 10.1111/apt.13477. 2016
Characteristics of the stricture, not the ongoing treatment, influence the outcome of endoscopic dilatation in recurrent Crohn's disease
Ladron Abia, P.; (...); Iborra, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.537. 2021
Decreased Esophageal Sensitivity to Acid in Morbidly Obese Patients: A Cause for Concern?
Ortiz, V; (...); Garrigues, V
Article. 10.5009/gnl16081. 2017
Different Genetic Expression Profiles of Oxidative Stress and Apoptosis-Related Genes in Crohn's Disease
Iborra, M; (...); Beltran, B
Article. 10.1159/000493726. 2019
Differential cytokine profiles and drop of faecal calprotectin for prediction of primary response to infliximab induction therapy in Crohn's disease
Mateos, B; (...); Beltran, B
Meeting Abstract. 10.1093/ecco-jcc/jjy222.725. 2019
Disease management and outcomes of patients with Crohn's disease at high risk of recurrence. Results from PRACTICROHN study
Iborra, M; (...); Julia, B
Meeting Abstract. 2017
DNA methylation signatures associated with pathogenesis Crohn's disease-related genes
Tatay, IM; (...); Beltran, B
Meeting Abstract. 2019
Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis
Taxonera, C; (...); Alba, C
Article. 10.1080/03007995.2019.1579557. 2019
Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply
Editorial Material. 10.1111/apt.15447. 2019
Efectiveness And Safety Of Ustekinumab In Elderly Patients With Crohn's Disease: Real World Evidence From The Eneida Registry.
Casas-Deza, Diego; (...); Garcia-Lopez, Y Santiago
Article. 10.1093/ecco-jcc/jjac108. 2022
Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn's Disease. Multicenter study based on the ENEIDA registry of GETECCU.
Guardiola Capon, J.; (...); Rodriguez-Moranta, F.
Meeting Abstract. 2024
Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-alpha: results from the ENEIDA registry
Mesonero, F; (...); Lopez-Sanroman, A
Article. 10.1111/apt.16315. 2021
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.
Casanova MJ; (...); Gisbert JP
Article. 10.1093/ibd/izz192. 2020
Effectiveness and Safety of the Switch from Remicade (R) to CT-P13 in Patients with Inflammatory Bowel Disease
Chaparro, M; (...); Gisbert, JP
Article. 10.1093/ecco-jcc/jjz070. 2019
Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.
Teresa VD; (...); Federico, Arguelles-Arias
Article. 10.1177/17562848231153560. 2023
Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry
Chaparro, M; (...); Esteve M
Meeting Abstract. 10.1093/ecco-jcc/jjz203.563. 2020
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients
Iborra, M; (...); Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).
Article. 10.1007/s00535-016-1274-1. 2017
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients (vol 52, pg 788, 2017)
Iborra, M; (...); Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).
Correction. 10.1007/s00535-016-1293-y. 2017
Effectiveness of Upadacitinib in Patients with Baseline Active Extraintestinal Manifestations and Inflammatory Bowel Disease. A multicenter retrospective study
Fuentes-Valenzuela, E.; (...); Barrio, J.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1180. 2025
Effectiveness of vedolizumab (VDZ) for the induction of remission in inflammatory bowel disease (IBD): Results from the Spanish Eneida Registry
Chaparro, M; (...); Gisbert, JP
Meeting Abstract. 2018
Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial.
Ginard, Daniel; (...); Sans, Miquel
Article. 10.1159/000540792. 2024
Efficacy of ustekinumab for the prevention of postoperative recurrence in crohn's disease. Data from clinical practice from the eneida registry
Ciria, MM; (...); Domenech, E
Meeting Abstract. 2020
Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: PRACTICROHN study
Barreiro-de Acosta, M; (...); Domenech, E
Meeting Abstract. 2018
Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: the Practicrohn study.
Barreiro-De Acosta, M; (...); Julia, B
Article. 10.1080/17474124.2019.1626717. 2019
Endoscopic treatment (endoscopic balloon dilation/self-expandable metal stent) vs surgical resection for the treatment of de novo stenosis in Crohn's disease (ENDOCIR study): an open-label, multicentre, randomized trial.
Loras C; (...); Esteve M
Article. 10.1186/s13063-023-07447-1. 2023
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity.
Guijarro LG; (...); Hernández-Breijo B
Article. 10.3390/biomedicines10030727. 2022
Evaluation of changes in intestinal microbiota in Crohn's disease patients after anti-TNF alpha treatment
Sanchis-Artero, L; (...); Cortes-Rizo, X
Article. 10.1038/s41598-021-88823-2. 2021
Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.
Article. 10.1016/j.gastrohep.2023.12.001. 2024
Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry
Chaparro, M; (...); Gisbert, JP
Article. 10.1038/ajg.2017.96. 2017
Extracolonic neoplasias in Inflammatory Bowel Disease patients: Data from the GETECCU ENEIDA registry
Chaparro, M.; (...); Gisbert, J. P.
Article. 2015
Faecal calprotectin and plasma cytokines in the prediction of early postoperative Crohn's disease recurrence
Cerrillo, E; (...); Beltran, B
Meeting Abstract. 2018
Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score
Cerrillo E; (...); Nos P
Article. 10.1097/MIB.0000000000000404. 2015
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Beltran, B; (...); Nos, P
Article. 10.1159/000492626. 2019
Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammatory Bowel Disease and Iron Deficiency without Anaemia.
Huguet JM; (...); Paredes JM
Article. 10.3390/jcm11102786. 2022
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease
Chaparro, M; (...); Gisbert, JP
Meeting Abstract. 2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease.
Chaparro M; (...); Gisbert JP
Article. 10.1177/1756284819867848. 2019
Granulocyte-monocyte apheresis combination therapy after loss of response to anti-TNF drugs
Rodriguez-Lago, I; (...); Cabriada, JL
Meeting Abstract. 2018
HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registry.
Calafat M; (...); Domènech E
Article. 10.14309/ajg.0000000000002965. 2024
Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn's Disease.
Moret-Tatay I; (...); Beltrán B
Article. 10.14309/ctg.0000000000000083. 2019
Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort study
de Paredes, AGG; (...); Lopez-Sanroman, A
Article. 10.1016/j.pan.2020.02.007. 2020
Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease
Saez-Gonzalez, Esteban; (...); Beltran, Belen
Review. 10.1007/s10620-017-4577-z. 2017
Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study
Domènech E; (...); Barreiro-de Acosta M
Article. 10.1097/MIB.0000000000001180. 2017
Incidence and risk factors of infection in patients with inflammatory bowel disease: longitudinal prospective INFEII registry of GETECCU
Zabana, Y.; (...); Esteve, M.
Meeting Abstract. 2024
Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study
Guerra, I; (...); Spanish GETECCU Grp
Article. 10.1097/MIB.0000000000000757. 2016
Inflammatory bowel disease in patients over the age of 70y. Does the disease duration influence its behavior?
Huguet, JM; (...); Paredes, JM
Article. 10.1080/00365521.2018.1501603. 2018
Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience
Barreiro-de Acosta, M; (...); Nos, P
Article. 10.1002/ueg2.12105. 2021
Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)
Gonzalez Vivo, M.; (...); Marquez, L.
Meeting Abstract. 2022
Infliximab serum levels do not predict remission after the induction phase in Crohn's Disease patients
Chaparro, M.; (...); Gisbert, J. P.
Article. 2015
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients
Lopez-Munoz, P; (...); Iborra, M
Article. 10.3390/nu11051059. 2019
Initial management of intraabdominal abscesses and preventive strategies for abscess recurrence in penetrating Crohn's disease: a national multicenter study based on ENEIDA registry.
Casas Deza, Diego; (...); Garcia-Lopez, Santiago
Article. 10.1093/ecco-jcc/jjad184. 2023
Intestinal tuberculosis simulating Crohn's disease: Differential diagnosis.
Garcia-Morales, N; (...); Iborra, M
Letter. 10.1016/j.gastrohep.2018.01.005. 2019
Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Chetwood, John David; (...); Leong, Rupert W
Article. 10.1093/ecco-jcc/jjae059. 2024
Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2023
Letter to the Editor on The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate-Severe Vulvar Lichen Sclerosus who were Non-Responders to Topical Clobetasol Propionate: A Randomized Pilot Study.
Gutierrez-Ontalvilla P; (...); Iborra M
Article. 10.1007/s00266-022-02960-1. 2022
Long-term effectiveness and safety of vedolizumab (VDZ) in inflammatory bowel disease (IBD): Results from the Spanish ENEIDA Registry
Chaparro, M; (...); Gisbert, JP
Meeting Abstract. 2018
Long-term follow-up of the PROTDILAT study; LONG-PROTDILAT Prospective multicenter randomized comparative study of endoscopic treatment of strictures in Crohn's disease (CD): self-expandable metal stent (SEMS) vs endoscopic balloon dilatation (EBD)
Ruiz Ramirez, P.; (...); Esteve, M.
Meeting Abstract. 2024
Long-term outcomes of biological therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU.
Acosta MB; (...); Rodríguez-Lago I
Article. 10.14309/ajg.0000000000002152. 2023
Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA
Gargallo-Puyuelo, C.; (...); Gomollon, F.
Meeting Abstract. 2023
Management and outcomes of patients with Crohn's disease with first vs multiple surgeries: results from the PRACTICROHN study
Iborra, M; (...); Domenech, E
Article. 10.1093/gastro/goz029. 2019
Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers
Pérez-Brocal V; (...); Moya A
Article. 10.1097/MIB.0000000000000549. 2015
MicroRNA and granulocyte-monocyte adsorption apheresis combotherapy after inadequate response to anti-TNF agents in ulcerative colitis.
Saez-Gonzalez, Esteban; (...); Beltran, Belen
Article. 10.1002/jca.22101. 2023
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry.
Zabana Y; (...); Esteve M
Article. 10.3390/jcm11020421. 2022
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
Ferreiro-Iglesias, Rocio; (...); Barreiro-de Acosta, Manuel
Article. 10.1111/apt.18133. 2024
Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease.
Article. 10.1016/j.giec.2016.06.005. 2016
Optimization through iv maintenance with ustekinumab in Inflammatory Bowel Disease. Efficacy and adjusted regimen in real world
Minguez, A.; (...); Bastida, G.
Meeting Abstract. 2024
Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world.
Minguez, Alejandro; (...); Bastida, Guillermo
Article. 10.1016/j.gastrohep.2024.502253. 2024
Oxidative Stress in the Pathogenesis of Crohn's Disease and the Interconnection with Immunological Response, Microbiota, External Environmental Factors, and Epigenetics
Alemany-Cosme, E; (...); Beltran, B
Review. 10.3390/antiox10010064. 2021
Plasma Oncostatin M, TNF-a, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop.
Mateos B; (...); Beltrán B
Article. 10.1159/000508069. 2020
Possible Biomarkers in Blood for Crohn's Disease: Oxidative Stress and MicroRNAs-Current Evidences and Further Aspects to Unravel
Moret-Tatay I; (...); Beltrán B
Review. 10.1155/2016/2325162. 2016
Prevalence, features and outcomes of splachnic vein thrombosis in inflammatory bowel disease. A nationwide, retrospective study from the ENEIDA registry
Masnou, H; (...); Eneida-GETECCU Registry
Meeting Abstract. 2020
Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study.
Sanz Segura, Patricia; (...); Garcia-Lopez, Santiago
Article. 10.1016/j.dld.2024.05.021. 2024
Quantification of the concentration of antibodies against Infliximab in human serum using a pure antibody as calibrator
Hernandez-Breijo, B.; (...); Guijarro, L.
Article. 2015
Real life effectiveness of Adalimumab for the treatment of ulcerative colitis: comparison between anti-TNF-naive and non-naive patients. Results from the Spanish ENEIDA Registry.
Iborra, M.; (...); Nos, P.
Meeting Abstract. 2015
Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients.
Article. 10.1038/s41598-020-73577-0. 2020
Real-life experience with long-term maintenance of golimumab in ulcerative colitis patients
Meeting Abstract. 10.1093/ecco-jcc/jjy222.683. 2019
Real-world effectiveness of vedolizumab in managing refractory pouchitis: a multicenter study on intravenous to subcutaneous transition
Gimeno-Pitarch, L.; (...); Iborra, M.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1018. 2025
Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry
Article. 10.1111/apt.15958. 2020
Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry
Iborra Colomino, M. I.; (...); Nos, P.
Meeting Abstract. 2020
Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
Iborra, Marisa; (...); Nos, Pilar
Article. 10.1080/00365521.2023.2278427. 2023
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry
Iborra, M; (...); Chaparro, M
Article. 10.1111/apt.15371. 2019
Real-world short-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA Registry
Meeting Abstract. 10.1093/ecco-jcc/jjy222.629. 2019
Real-world subcutaneous infliximab for inflammatory bowel disease: A systematic review and meta-analysis
Chetwood, J.; (...); Leong, R.
Meeting Abstract. 2023
Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry.
Hernandez-Camba, A.; (...); GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa)
Article. 10.1016/j.dld.2021.10.002. 2021
Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease.
Boscá MM; (...); Hinojosa J
Review. 10.1016/j.gastrohep.2019.09.012. 2020
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients
Barreiro-de Acosta, M; (...); Gisbert, JP
Review. 10.1016/j.gastrohep.2017.10.003. 2018
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis.
Barreiro-de Acosta M; (...); Nos P
Editorial Material. 10.1016/j.gastrohep.2019.08.001. 2019
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment.
Barreiro-de Acosta M; (...); Nos P
Article. 10.1016/j.gastrohep.2020.04.004. 2020
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease
Guardiola, J; (...); Representacion GETECCU
Review. 10.1016/j.gastrohep.2018.05.029. 2018
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved.
Guijarro, Luis G.; (...); On Behalf Of The Predicrohn Study Group From Geteccu
Article. 10.1016/j.biopha.2021.112239. 2021
Risk of postoperative morbidity in patients having bowel resection for colonic Crohn's disease
Iesalnieks I; (...); El-Hussuna A
Article. 10.1007/s10151-018-1904-0. 2018
Role of Interleukin-8 in Predicting Long-Term Response to Vedolizumab in Ulcerative Colitis Patients
Minguez, A.; (...); Nos, P.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1111. 2025
Secondary Haemophagocytic Syndrome and Overlapping Immune Reconstitution Syndrome: Life-Threatening Complications of Anti-TNF-alpha Treatment for Crohn's Disease
Saez-Gonzalez, E; (...); Beltran, B
Letter. 10.1038/s41395-018-0420-1. 2019
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Aguas Peris M; (...); Nos, P
Article. 10.1097/MIB.0000000000001182. 2017
Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice
Meeting Abstract. 2017
Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
Bosca-Watts, MM; (...); Paredes, JM
Article. 10.3748/wjg.v22.i47.10432. 2016
Specific plasma micro-RNA profiles for prediction of recurrence in Crohn's disease in pre-surgery and established recurrence scenarios
Moret, I; (...); Beltran, B
Meeting Abstract. 2020
Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications.
Moret-Tatay, Ines; (...); Beltran, Belen
Article. 10.14309/ctg.0000000000000416. 2021
Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review
Puig, Maria; (...); Domenech, Eugeni
Review. 10.3390/jcm12237366. 2023
Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab
Hernandez-Breijo, B; (...); Guijarro, LG
Article. 10.1016/j.bcp.2016.019. 2016
Stopping azathioprine in monotherapy after very prolonged remission in inflammatory bowel disease patients: Novel relapse risk factors
Meeting Abstract. 2018
Subcutaneous infliximab cut-off points in a large cohort of Spanish patients with inflammatory bowel disease and factors associated with long-term outcomes
Iborra, M.; (...); Nos, P.
Meeting Abstract. 2024
Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry.
Article. 10.1093/ecco-jcc/jjae127. 2024
Switching from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease in clinical remission: a multicenter study from GETECCU
Gros, B.; (...); Iglesias-Flores, E.
Meeting Abstract. 2024
Switching to standard-dose subcutaneous vedolizumab increases the percentage of patients in biochemical remission even in those intensified with intravenous vedolizumab: one year results of a Spanish multicentre observational study
Andres Pascual, L.; (...); Sicilia, B.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1000. 2025
Terapia de rescate con ciclosporina oral tras el uso de ustekinumab en colitis ulcerosa resistente a múltiples tratamientos.
Abia PL; (...); Niclós BB
Letter. 10.1016/j.gastrohep.2021.04.012. 2021
The characteristics of the stricture, but not the ongoing treatment, could influence the outcome of endoscopic dilation in recurrent Crohn's disease.
Ladron Abia, Pablo; (...); Iborra, Marisa
Article. 10.1016/j.gastrohep.2022.01.004. 2022
The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate-Severe Vulvar Lichen Sclerosus who were Non-Responders to Topical Clobetasol Propionate: A Randomized Pilot Study.
Gutierrez-Ontalvilla, P.; (...); Iborra, M.
Article. 10.1007/s00266-021-02718-1. 2022
The Female Sexual Function Index to assess patients with moderate to severe vulvar lichen sclerosus.
Gutierrez-Ontalvilla P; (...); Vicente D
Letter. 10.1684/ejd.2019.3580. 2019
Therapeutic drug monitoring during induction therapy with Ustekinumab in patients with Crohn's disease: the key to early identification of patients with inadequate response
Minguez, A.; (...); Nos, P.
Meeting Abstract. 2023
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis.
Rodríguez-Moranta F; (...); Gutiérrez Casbas A
Practice Guideline. 10.1016/j.gastrohep.2024.01.007. 2024
Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?
Ferreiro Iglesias, R.; (...); Barreiro-de Acosta, M.
Meeting Abstract. 2022
TREATMENT OF IRON DEFICIENCY WITHOUT ANEMIA WITH FERRIC CARBOXYMALTOSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: PROSPECTIVE EVALUATION OF CLINICAL AND PATIENT-REPORTED OUTCOMES IN SPAIN
Huguet, J. M.; (...); Munoz, M.
Meeting Abstract. 2022
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.
Gomez-Labrador, Celia; (...); Gisbert, Javier P
Article. 10.3390/pharmaceutics16050629. 2024
Use of Magnetic Resonance Index of Activity (MaRIA) in the preoperative assessment of small bowel Crohn's disease.
Pous-Serrano, S; (...); Garcia-Granero, E
Article. 10.1016/j.ciresp.2019.06.018. 2019
Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry
Camba, AH; (...); Ramos, L
Meeting Abstract. 2020
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
Chaparro, M; (...); Gisbert, JP
Article. 10.1097/MEG.0000000000001706. 2020
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry.
Manosa, Miriam; (...); Domenech, Eugeni
Article. 10.1016/j.dld.2022.07.013. 2022
Ustekinumab as an opportunity for refractory Ulcerative Colitis patients
Iborra, M.; (...); Nos, P.
Meeting Abstract. 2022
Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients
Mateos, B.; (...); Beltran, B.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.697. 2021
Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patients
Meeting Abstract. 2018
Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents
Article. 10.1016/j.gastrohep.2018.06.001. 2018
Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse
Article. 10.1007/s10620-018-5429-1. 2019